6-K ·Filed Jul 9, 2026

GSK

GSK plc
NEUTRAL
Impact 2/10
Horizonimmediate Processed2mo ago SEC0001654954-26-006557
Notable filing: 6-K
Actionable Insight • Neutral

This is a standard independent director appointment with no trading signal. No further action warranted — monitor for any future association with Philips-related partnerships or M&A, but not an event for immediate positioning.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d ⚠ clustered
GSK ▼ -10.37% at T+60d
NEUTRAL call ✗ call lost -10.37% · α vs SPY -12.00% · entry $52.47 → $47.03
Entry anchored
Jul 8, 03:59 PM ET
via exchange tick
T+1d
+0.59%
call +0.59% · α +0.16%
$52.78
settled 3mo ago
T+5d
+0.57%
call +0.57% · α +0.70%
$52.77
settled 3mo ago
T+20d
-0.57%
call -0.57% · α -2.81%
$52.17
settled 8w ago
T+60d
-10.37%
call -10.37% · α -12.00%
$47.03
settled 9h ago

Price Chart

Loading chart...

Executive Summary

GSK announced the appointment of Roy Jakobs, CEO of Royal Philips, as an independent Non-Executive Director effective July 13, 2026. This is a routine board addition bringing health technology expertise, with no material financial impact or strategic change.

Key Facts

  • Roy Jakobs to join GSK board as independent Non-Executive Director from July 13, 2026
  • Jakobs is currently CEO of Royal Philips (EUR 17.8B sales in 2025, 65,000 employees)
  • Standard annual fee of £122,258 for the non-executive role
  • Board expands to 13 members as of the effective date

Financial Impact

No material financial figures; annual director fee of £122,258 is immaterial for a $106B market cap company

Risk Factors

  • None identified from this filing alone

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
43% bullish (30 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-006557
Document: 0001654954-26-006557-index-headers.html0001654954-26-006557
Document: 0001654954-26-006557-index.html0001654954-26-006557
Document: 0001654954-26-006557.txt0001654954-26-006557
42 reports for GSK
Performance horizon
69% Hit rate 11 of 16 directional calls best @ T+60▲ +7.85%Jun 16, 2026
Filters
Rows
Reports for GSK — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
6-K
NEUTRAL ★ 5/10
$50.01 $50.22▲ +0.42%▼ −0.40%$47.03 (−5.96%)
Sep 14, 2026
18d ago
6-K
BULLISH ★ 7/10
$50.05 $51.08▲ +2.06%▲ +1.95%$47.03 (−6.03%)
Sep 14, 2026
18d ago
6-K
BULLISH ★ 7/10
$50.05 $51.08▲ +2.06%▲ +1.95%$47.03 (−6.03%)
Sep 11, 2026
21d ago
6-K
NEUTRAL ★ 1/10
$48.13 $50.22▲ +4.34%▲ +4.56%$47.03 (−2.29%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 1/10
$48.12 $51.06▲ +6.11%▲ +6.61%$47.03 (−2.27%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 3/10
$48.12 $51.06▲ +6.11%▲ +6.61%$47.03 (−2.27%)
Sep 1, 2026
4w ago
6-K
NEUTRAL ★ 1/10
$50.66 $48.63▼ −4.01%▼ −4.09%$47.03 (−7.17%)
Sep 1, 2026
4w ago
6-K
BULLISH ★ 6/10
$50.66 $48.63▼ −4.01%▼ −4.09%$47.03 (−7.17%)
Aug 26, 2026
5w ago
6-K
NEUTRAL ★ 1/10
$51.43 $50.44▼ −1.92%▼ −1.80%$47.03 (−8.56%)
Aug 24, 2026
5w ago
6-K
NEUTRAL ★ 2/10
$51.78 $50.25▼ −2.95%▼ −3.42%$47.03 (−9.17%)
Showing 10 of 42

US Market Status

Market Closed — Opens Mon (64h 22m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access